

Cite this: *Chem. Sci.*, 2026, 17, 3572

All publication charges for this article have been paid for by the Royal Society of Chemistry

Characterization of the ketoreductase domain of pikromycin module 2

Eiji Okamura,^a Kosuke Ohsawa,^{bc} Hidetoshi Ban,^b Yoshiyuki Sugiyama,^b Junko Hashimoto,^d Kei Kudo,^{ef} Masahito Yoshida,^g Kazuo Shin-ya,^{ef} Haruo Ikeda,^{†h} Shunji Takahashi^{ia} and Takayuki Doi^{ib}

Polyketides represent a diverse class of natural products that serve as major sources of medicinal compounds. Their biosynthesis is generally catalyzed by multimodular polyketide synthase comprising functional domains, such as a β -ketosynthase, an acyltransferase, and an acyl carrier protein. These domains mediate the elongation of polyketide chains via decarboxylative Claisen-like condensation. A reductive loop comprising β -ketoreductase (KR), dehydratase (DH), and enoyl reductase domains converts the β -keto group into a hydroxy group, alkene, and alkane, respectively. Particularly, the KR domains are pivotal in determining the stereochemical configurations of the hydroxy and methyl groups on the macrolide backbone and are classified into A1, A2, B1, B2, and C types. In this study, we performed a reductive loop exchange using pikromycin PKS, PikAIII module 5 (PikAIII-M5) as a template. The PikAIII-M5 was derived from the pikromycin biosynthetic gene cluster of the pikromycin-producing *Streptomyces* sp. AM4900. Next, we constructed a chimeric enzyme by replacing the KR domain of PikAIII-M5 with a DH-KR di-domain derived from PikAI module 2 (PikAI-M2), followed by the artificial addition of a thioesterase domain derived from PikAIV module 6. Thereafter, we evaluated the enzymatic activity of the construct using various chemically synthesized *N*-acetylcysteamine substrate analogs. This demonstrated that the chimeric module enzyme catalyzed the formation of (2*R*,3*R*,4*S*)-3-hydroxy-2,4-dimethylheptanoic acid, indicating that the KR domain of PikAI-M2 is a B1-type. These findings offer insights into the unresolved classification of KR domains that do not strictly conform to the Caffrey motif.

Received 26th September 2025

Accepted 10th December 2025

DOI: 10.1039/d5sc07470c

rsc.li/chemical-science

Introduction

Macrolide antibiotics, which contain a macrolactone aglycone, as well as sugar moieties, are a class of biologically active polyketide products.¹ Contemporary organic synthesis faces significant challenges in modifying functional groups and controlling the stereochemistry of macrolactone rings. To address these limitations, the

biosynthetic engineering of natural products represents a valuable approach for accessing otherwise inaccessible chemical spaces within polyketide core scaffolds.²⁻⁵ Notably, the first macrolide antibiotic, pikromycin, was isolated in 1950.^{6,7} Pikromycin is biosynthesized by a modular type-I polyketide synthase (PKS), as illustrated in Fig. 1.⁸⁻¹⁰ Each module comprises β -keto synthase (KS), acyltransferase (AT), and acyl carrier protein (ACP) domains, which facilitate the elongation of the polyketide chain via decarboxylative Claisen-like condensation. Additional domains, such as β -ketoacyl-ACP reductase (KR), dehydratase (DH), and enoyl reductase (ER) domains, sequentially convert the β -keto group into hydroxy, alkene, and alkane functionalities, respectively. Further, a thioesterase (TE) in module 6 releases narbonolide, a 14-membered-ring biosynthetic precursor of pikromycin. Interestingly, the pikromycin PKS can also generate 10-deoxymethynolide, a 12-membered-ring biosynthetic precursor of methymycin (Fig. 1). These structural variations are valuable for assembling the macrolactone cores of polyketides through PKS engineering. The PikAIII module of pikromycin PKS, comprising KS-AT-KR-ACP domains, has been modified to produce the hybrid modular enzyme, PikAIII-M5-TE, a biocatalyst for homologation and lactonization reactions.^{11,12} The structural variations of macrolides depend on the stereochemistry of the functional groups on their macrolactone

^aNatural Product Biosynthesis Research Unit, RIKEN Center for Sustainable Resource Science, Saitama 351-0198, Japan. E-mail: shunjitaka@riken.jp

^bGraduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aza-aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan. E-mail: doi_taka@mail.pharm.tohoku.ac.jp

^cFaculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu 279-0013, Japan

^dJapan Biological Informatics Consortium, Koto-ku, Tokyo, Japan

^eNational Institute of Advanced Industrial Science and Technology (AIST), 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan

^fBiotechnology Research Center, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan

^gDepartment of Chemistry, Institute of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8571, Japan

^hKitasato Institute for Life Sciences, Kitasato University, 1-15-1 Kitasato, Minami-ku, Sagami-hara, Kanagawa 252-0373, Japan

[†] Present address: Technology Research Association for Next generation natural products chemistry, 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan.






Fig. 1 Pathway for pikromycin biosynthesis. ACP: acyl carrier protein, AT: acyltransferase, DH: dehydratase, ER: enoyl reductase, KR: β -ketoacyl-ACP reductase, KS: β -ketoacyl-ACP synthase, KS^Q: KS-like domain (active motif, CSSSL, is converted into QSSSL), KR*: dysfunctional KR, and TE: thioesterase.

ring. In the PKS assembly line, the reductive loop, defined as the KR, KR-DH, or KR-DH-ER domain, plays a crucial role in determining the reduction degree of the β -carbonyl group formed by the decarboxylative Claisen-like condensation of the KS domain.¹³⁻¹⁵ Furthermore, the β -position hydroxylation of a carboxyl moiety by A- and B-type KR generates *L*- and *D*-configured alcohols, respectively. The functions of KR domains are further categorized into two groups based on the final orientation of their α -substituents: A1/B1-

and A2/B2-type KR that generate *D*- and *L*-configured α -substituents, respectively.^{13,16} Dissimilar to these KR domains, C-type KR lack reductase activity, although they can still function as epimerases.¹³ The functions of KR can be distinguished based on their characteristic amino acid-sequence motifs.^{15,17} Although the LDD motif is conserved in B-type KR domains, it is absent in A-type KR, which contain a W motif instead. The functions of KR are further classified based on the presence or absence of the H (defining A1 or



A2 types) and P (defining B1 or B2 types) motifs. Therefore, exchanging the KR-domain type within module enzymes represents a central strategy for controlling the stereochemistry of polyketide chains. This strategy generally relies on well-established sequence motifs, such as the Caffrey motif, to predict stereochemical outcomes.¹⁷ KR domains containing an XXD sequence within the LDD motif are summarized in Fig. S1. Based on structural analyses of various KR domains, only the third Asp residue of the LDD motif is required for classification as a B-type KR.^{18,19} This finding also suggests that XXD motifs such as SKD²⁰ and VAD²¹ can be defined as a B-type KR domain and may function to orient the pantetheine arm of the substrate through hydrogen bonding. Indeed, CmiP2 KR has been experimentally demonstrated to be B-type. Additionally, the presence of a nearby proline residue classifies a KR as B2-type, whereas its absence classifies it as B1-type. The KR domain of pikromycin PKS module 2 (PikAI-M2) is an example of the XXD-type KR domain lacking the P motif, suggesting that it belongs to the B1-type. However, its classification should be validated by experimental evidence. Historically, the *in vitro* enzymatic activity of PikAI-M2 was indirectly demonstrated in a study exploring the substrate specificity of KS domains, where the PikAI-M2 functioned as the enzyme responsible for supplying the substrate for target modules enzymes.²² The use of malonyl-CoA as the extender substrate for PikAI-M2 in this experiment resulted in a polyketomethylene chain with no methyl group at the α -position. Consequently, it was not possible to determine the epimerase activity of the PikAI-M2 KR domain towards the α -methyl group. In addition, the stereochemical configuration at the β -carbon was elucidated through detailed enzymatic analyses based on the investigation of the enzymatic activity of the DH- or KR-domain-inactivated mutant, PikAI-M2,²³


and by studying KR activity in PKSs using a novel set of chemical probes.²⁴ The results revealed that the KR domain of PikAI-M2 was a B-type. Despite these extensive analyses, the stereochemical outcome at the α -position remains unresolved. As the two experiments were conducted using only malonyl-CoA as an extender substrate, it is still unclear whether this KR domain yields a B1- or B2-type product. In this study, to obtain experimental evidence of the stereochemistry of the α -methyl group introduced by the KR domain of PikAI-M2, we performed an *in vitro* enzymatic reaction using synthetic substrates.

As an initial step, we evaluated the enzymatic activity and substrate specificity of an *E. coli*-expressed recombinant enzyme, PikAIII-M5-TE, from *Streptomyces* sp. AM4900 (ref. 25 and 26) using various chemically synthesized *N*-acetylcysteamine (NAC) substrate analogs. To achieve the stereochemical inversion of the products generated by PikAIII-M5-TE, we constructed a chimeric module enzyme, PikAIII-M5 Δ KR5::DH2-KR2-TE, by replacing the KR domain of PikAIII-M5-TE with the reductive loop (the DH-KR di-domain) from PikAI-M2. Analysis of the product revealed that the chimeric enzyme, when supplied with the NAC analog, *S*-(2-acetamidoethyl) (*S*)-2-methylpentanethioate, catalyzed the formation of (2*R*,3*R*,4*S*)-3-hydroxy-2,4-dimethylheptanoic acid. These results enabled us to elucidate stereochemistry of the α -position methyl group, classifying the KR domain of PikAI-M2 as a B1-type.


Results

Synthesis of *N*-acetylcysteamine substrates for enzymatic reactions

Our retrosynthetic analysis of the NAC ester **1a** is illustrated in Scheme 1. Although the thioesterification of enone-bearing




Scheme 1 Retrosynthetic analysis of **1a**.



Scheme 2 Synthesis of **3**.





Scheme 3 Synthesis of the NAC ester, 13a, and the accompanying undesired lactonization.

carboxylic acids has been reported without side reactions,^{27,28} accomplishing this with more electrophilic enones might be challenging owing to the 1,4-addition of thiols.^{29–33} Thus, we first condensed **2** with NAC before oxidizing the allylic alcohol in **2** into the corresponding enone. The allylic alcohol **2** was obtained *via* the Nozaki–Hiyama–Kishi (NHK) coupling of vinyl iodide **3** with aldehyde **4**.

The vinyl iodide was prepared, as shown in Scheme 2. The Evans aldol reaction³⁴ of the boron enolate (produced by the known *N*-acylated chiral oxazolidinone **5** (ref. 35)) with propanal yielded *syn*-enriched **6**, with good yield (86%) and diastereoselectivity (dr > 95 : 5). The resulting hydroxy group in **6** was protected by a *tert*-butyldimethylsilyl (TBS) group to yield the silyl ether **7** in a 92% yield. Further, the reductive cleavage of

the chiral oxazolidinone by LiBH₄ yielded the alcohol **8** in a 69% yield. Furthermore, the oxidation of the primary alcohol into an aldehyde with Dess–Martin periodinane,^{36,37} followed by Takai olefination,^{38,39} yielded **3** in a 47% yield over two steps. The *trans* geometry of the alkene in **3** was determined by ¹H NMR spectroscopy through a large coupling constant ($^3J_{\text{H,H}} = 14.5 \text{ Hz}$).

After synthesizing **3**, we performed the convergent synthesis of the NAC thioester **1a** *via* NHK coupling, as depicted in Scheme 3. The optically active alcohol **9** (93% ee), which was obtained *via* the enzymatic desymmetrization of the corresponding *meso*-diol,⁴⁰ was oxidized using Dess–Martin periodinane to yield **4** in a 53% yield. The NHK coupling of **4** with 2.0 equivalents of **3** in the presence of a catalytic amount of nickel(II) chloride and an excess amount of chromium(II) chloride



yielded the allylic alcohol **10** in 77% yield as a 1 : 1 diastereomeric mixture. As the allylic alcohol moiety in **10** can be subsequently converted into an enone, these diastereomers were utilized without separation. The protection of the hydroxy group in **10** by a TBS group furnished the silyl ester **11a** in a 94% yield. Following the deacetylation of **11a** *via* basic methanolysis, the two-step oxidation of the resulting primary alcohol **12a** yielded the carboxylic acid **2a** in a 72% yield. Thioester **13a** was obtained by coupling **2a** with NAC using 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI)·HCl/4-(dimethylamino)pyridine (DMAP) without epimerization at the α -position. The two TBS groups in **13a** were removed by HF·pyridine/pyridine before the formation of the enone **1a**. However, the resulting allylic alcohols (5*R*)-**14a** and (5*S*)-**14b** were unstable. The (5*R*)-**14a** isomer was readily cyclized to yield the six-membered-ring lactone (5*R*)-**15a**.^{41–43} The large coupling constant between the allylic and adjacent protons ($^3J_{\text{H,H}} = 10.3$ Hz) indicated the equatorial orientation of all substituents in (5*R*)-**15a**. Surprisingly, the six-membered lactone derived from (5*S*)-**15b** was not isolated, as it decomposed during the reaction or *in vacuo* solvent removal. Other acidic conditions for removing the TBS groups (aqueous HF/CH₃CN and AcOH/THF/H₂O) were also ineffective.

To resolve the undesirable lactonization of **14a**, we performed the direct conversion of the silyl ether into an enone (Scheme 4). Considering the chemoselective removal of the allylic silyl ether, we selected a triethylsilyl (TES) group as the allylic-alcohol-protecting group. Thus, the TES-protected **11b** was synthesized by treating **10** with triethylsilyl trifluoromethanesulfonate (TESOTf)/2,6-lutidine. Further conversions, including the oxidation of a primary alcohol into a carboxylic acid and thioesterification with NAC, were performed in the same manner as for **13a**, yielding the NAC ester **13b**. Next, we removed the TES group in **13b** and oxidized the resulting alcohols *via* a one-pot reaction with 2-iodoxybenzoic


acid (IBX) in DMSO^{44,45} to yield the enone without forming a lactone. Finally, we synthesized **1a** in an 82% yield by removing the TBS group using aqueous HF over two steps.

Enzymatic conversion of the *N*-acetylcysteamine thioester into 10-deoxymethynolide

To confirm the function of the PikAIII-M5-TE chimera enzyme obtained from *Streptomyces* sp. AM4900 (Fig. S2–S4), we performed an enzymatic reaction using synthetic **1a** and methylmalonyl-NAC (**16**), as shown in Fig. 2. We confirmed the conversion of substrate **1a** ($[M + H]^+ = 358.2$) into product **17** ($[M + H]^+ = 297.2$) by ultra-performance liquid chromatography–mass spectrometry (UPLC–MS) analysis (Fig. 2). Further, the scale-up enzymatic reaction, isolation, and NMR analysis of **17** indicated that its structure corresponded to 10-deoxymethynolide.⁴⁶ The absence of methylmalonyl-NAC (**16**) in the reaction mixture completely terminated the enzymatic reaction.

Evaluation of substrate specificity of PikAIII-M5-TE

We explored PikAIII-M5-TE chimera enzyme as a template module enzyme for reductive loop exchange by first evaluating its primer substrate specificity using a set of NAC primer substrates, including physiological substrates (**1a**, **1c**, and **1f**) and analogous substrates (**1b**, **1d**, **1e**, and **1g**), for various PKS modules, such as PikAI-M2, PikAII-M3, PikAII-M4, and PikAIII-M5 (Fig. 3A). As mentioned above, we obtained a reaction product from **1a** ($[M + H]^+ = 297$), and its structure was resolved to be 10-deoxymethynolide (**17**).⁴⁷ Reaction products **18a**, **19**, **20**, and **21**, with m/z 173 $[M - H]^-$, m/z 215 $[M - H]^-$, m/z 159 $[M - H]^-$, and m/z 157 $[M - H]^-$, were detected from **1b**, **1c**, **1d**, and **1e**, respectively. In addition, triketide lactone product **22**, with m/z 171.1 $[M - H]^-$, were detected from **1f** (Fig. S7 and Table 1). Conversely, no reaction product was detected from **1g** (Fig. 3A and Table 1).



Scheme 4 Synthesis of the NAC ester, **1a**.






Fig. 2 Enzymatic reaction of the NAC ester, **1a**, with recombinant pikromycin module 5-TE (PikAIII-M5-TE). (a) Enzymatic synthesis of 10-deoxymethynolide (**17**) using recombinant PikAIII-M5-TE. (b) UPLC-MS analysis of the PDA spectra (226 nm) of PikAIII-M5-TE. The red and black lines represent enzyme reactions in the presence and absence (negative control) of methylmalonyl-NAC (**16**), respectively. (c) Selected ion monitoring (SIM) spectra (left panel) and mass spectra (right panel) of **17** ($[M + H]^+ = 297.2$) after the reaction in the presence of **16**. (d) SIM spectra (left panel) and mass spectra (right panel) of **1a** ($[M + H]^+ = 358.2$) after the reaction in the absence of **16**.






Fig. 3 UPLC–MS analyses of reactions catalyzed by PikAIII–M5–TE (a) and PikAIII–M5 Δ KR5::DH2–KR2 (b) using synthetic NAC primer substrates. The extracted-ion chromatograms were generated by filtering the data for masses within a tolerance of $m/z \pm 0.5$ of predicted reaction products. The line numbers (Table 1) in each panel indicates reaction mixtures containing primer substrates as follows: **1a** (purple); M5 substrate NAC, **1b** (dark green); M5 analog substrate NAC **1c** (dark khaki); M3 substrate NAC, **1d** (brown); M5 analog substrate NAC **2**, **1e** (light green); M3 analog substrate NAC, **1f** (dark gray); M2 substrate NAC, **1g** (orange); M2 analog substrate NAC. The retention times for the products are as follows: **17**, 3.7 min; **18a**, 3.2 min; **19**, 2.6 min; **20**, 2.9 min; **18b**, 3.2 min; **21**, 2.7 min. Dashed lines indicate reaction mixture without methylmalonyl–CoA. The total mass spectra in each retention time are summarized in Fig. S6. All analyses were performed in negative ion mode except for **1a**, which was detected in the positive ion mode.

Evaluation of substrate specificity of PikAIII–M5– Δ KR5::DH2–KR2–TE

We predicted that exchanging the A1-type KR domain for a B-type KR domain would result in a stereochemical conversion at the β -position of the hydroxy group. Thus, we replaced the A1-type KR domain of PikAIII–M5–TE with the reductive loop of the DH2–KR2 di-domain from PikAI–M2 to generate the chimera module enzyme, PikAIII–M5 Δ KR5::DH2–KR2–TE. To assess the activity of this module enzyme, it was heterologously expressed in *E. coli* and purified *via* Ni-affinity chromatography (Fig. S5). Thereafter, the enzymatic reaction product was analyzed using the primer substrate (Table 1, **1a–1g**) and extender substrate (methylmalonyl–CoA). The result revealed that only the peak

corresponding to the hydroxylated product, **18b**, was detected in the reaction of **1b** with PikAIII–M5– Δ KR5::DH2–KR2–TE (Fig. 3B).















To determine the chemical structure of **18b**, we performed a large-scale enzymatic reaction to isolate **18b**, after which NMR revealed that the product **18b** was (2*R*,3*R*,4*S*)-3-hydroxy-2,4-dimethylheptanoic acid (Fig. S8 and S9). The result indicated that the KR domain of PikAI–M2 was a B1-type.

Discussion

In the enzymatic reactions of PikAIII–M5–TE, we hypothesized that all substrates would be converted to reaction products, as PikAIII–M5–TE naturally accepts the polyketomethylene chain of **1a**. We also hypothesized that other synthetic substrates could



Table 1 Substrates and products from the substrate-specificity-determination experiments using PikAIII-M5-TE (Method A) and PikAIII-M5-ΔKR5::DH2-KR2-TE (Method B). ND means not detected

Substrate	Product	
	Method A	Method B
 1a	 10-deoxymethynolide (17)	ND
 1b	 (2R,3S,4S)- 18a	 (2R,3R,4S)- 18b
 1c	 19	ND
 1d	 20	ND
 1e	 21	ND
 1f	 22	ND
 1g	ND	ND

function as substrates since they exhibit smaller molecular sizes than **1a**. However, contrary to our prediction, our MS analysis did not detect any reaction product from substrate **1g**. Yin *et al.* reported that a chimeric module enzyme, which is a homolog of PikAIII-M5-TE, produced a triketide lactone.¹² Among the four primer substrates exhibiting different configurations at the α - and β -positions: (2S,3S), (2S,3R), (2R,3S), and (2R,3R), the triketide lactone was produced from (2S,3R). The (2S,3R) stereoisomer was identical to **1f**.¹² Therefore, our results correlated with those of the literature. Although the stereochemistry of the β -functional group on the primer substrate was initially assumed to

account for the reactivity of PikAIII-M5-TE reaction systems, our experimental results attributed the reactivity of PikAIII-M5-TE to the presence or absence of the β -keto group.

The KR domain of PikAI-M2 was initially presumed to be type B based on sequence information,^{20,21} and the structure of its product also supported this classification.²² However, because the natural substrate is malonyl-CoA, it was not possible to obtain experimental evidence to distinguish between B1 and B2 types. In this study, experimental designs using methylmalonyl-CoA and synthetic substrates demonstrated that KR domain of PikAI-M2 is a B1 type. This finding



represents the most significant result of our work, as KR-domain types have previously been determined only by detecting D-hydroxylated products. Notably, epimerization of the methyl group in a product synthesized by Claisen-like condensation of the KS domain on a module enzyme had not been reported experimentally. Our analysis of the chimeric module enzyme, PikAIII-M5ΔKR5::DH2-KR2-TE, therefore provides conclusive evidence that the KR domain of PikAI-M2 is a B1 type. Intriguingly, a database search revealed seven other KR domains that, like the PikAI-M2 KR domain, share the XXD motif and lack a P motif (Fig. S1).

The chimeric module enzyme produced the hydroxylated product (**18b**) from **1b** but not the dehydrated product, consistent with prior reductive-loop swapping studies. Previous reductive-loop swap studies (DH-ER-KR) have shown that DH catalyzed dehydration is the rate-limiting step, and that this bottleneck can be rescued by selecting a compatible DH. These studies also suggested that DH domains generally exhibit high substrate specificity.⁴⁸ In addition, the Pik-DH2 domain has been reported to display high substrate specificity.⁴⁹ In our chimeric module enzyme, the DH2 domain must dehydrate the β-hydroxy intermediate generated after methylmalonyl-CoA incorporation. Therefore, our results likely reflect insufficient compatibility of DH2 with this noncognate intermediate. Consequently, dehydration would not proceed efficiently, leading to accumulation of the hydroxylated intermediate. Notably, substrate-reductive-loop incompatibility can manifest at different steps depending on the substrate presented to the reductive loop. In the case of the smaller substrate (**1b**), dehydration appears to be the primary bottleneck; however, when a bulkier substrate is supplied, failure may occur earlier in the reductive sequence. Consistent with this substrate-dependent shift, no product was detected in the reaction of the chimeric module enzyme with **1a**, which we interpret this as follows. As shown in Fig. 3B, no reaction intermediates were detected when **1a** was used, indicating that the KR2 reaction (and thus subsequent DH2 dehydration) did not proceed. Because the cognate PikAI-M2 substrate is relatively small, the active-site architecture of the KR2-DH2 chimera likely cannot accommodate the bulkier **1a** substrate. Given that KR domains act as gatekeepers in reductive-loop processing,¹⁹ we infer that poor substrate compatibility at the KR2 step is the main reason for the lack of detectable product.

Although including chimeras bearing canonical B1- or B2-type KR domains (or KR-DH pairs) as controls would further strengthen our comparisons, prior studies show that single-KR swaps often result in poor functional recovery, whereas larger domain replacements are more successful.^{20,48,50} Structurally, this trend is consistent with evidence that KR domains within DH/ER-containing reductive loops are stabilized through mutual interactions.^{51,52} A recent comprehensive study did report successful single exchanges of various KR domains, including B1-type KR domains.⁵³ However, all B1-type donor KR domains were originally isolated within their native modules (*i.e.*, not paired with an active DH domain), except for ty lactone module 1, where the DH is inactive. Thus, excising a KR domain from an intact, active DH-KR reductive loop, such as the PikAI-M2 loop,

remains untested,⁵³ and is expected to disrupt stabilizing interactions, likely leading to inactivation. We therefore prioritized the KR2-DH2 replacement to evaluate KR2-dependent outcomes. Notably, because DH2 was not functionally expressed in this chimera, the observed product profile primarily reflected KR2 activity, allowing us to evaluate B1/B2-type behavior as intended. For more detailed future analyses, it will be important to assess the effects of single-domain swaps as controls. We plan to address this in future work.

Materials and methods

Chemical synthesis

(2S,4R)-2,4-Dimethyl-5-oxopentyl acetate (4). To a solution of the alcohol **9** (ref. 40) (300 mg, 1.59 mmol, 1.0 equiv) in dry CH₂Cl₂ (15 mL) were added Dess–Martin periodinane (870 mg, 2.07 mmol, 1.3 equiv) and NaHCO₃ (400 mg, 4.78 mmol, 3.0 equiv) at room temperature under an argon atmosphere. After being stirred at the same temperature for 40 min, the reaction mixture was quenched with saturated aqueous NaHCO₃ and 20% aqueous Na₂S₂O₃. The organic layer was separated, and the aqueous layer was extracted twice with CH₂Cl₂. The combined organic layers were washed with saturated aqueous NaHCO₃ and brine, dried over MgSO₄, and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 3/1) to afford the aldehyde **4** (170 mg, 910 μmol, 53%) as a colorless oil. The spectral data of the synthetic **4** were in good agreement with those of reported.⁵⁴ [α]_D²⁰ +3.6 (c 0.80, CHCl₃) [lit. [α]_D²⁵ +3.6 (c 0.85, CHCl₃)]; ¹H NMR (400 MHz, CDCl₃) δ 9.60 (d, 1H, *J* = 2.2 Hz), 3.87–3.96 (m, 2H), 2.44–2.52 (m, 1H), 2.06 (s, 3H), 1.80–1.93 (m, 2H), 1.17–1.26 (m, 1H), 1.13 (d, 3H, *J* = 6.8 Hz), 0.96 (d, 3H, *J* = 6.6 Hz); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 204.5, 171.1, 68.8, 43.8, 34.4, 30.2, 20.8, 17.1, 14.2; IR (neat) 2967, 1738, 1461, 1368, 1239, 1038 cm⁻¹; HRMS[FAB] *m/z* calcd for C₉H₁₅O₃ [M – H]⁺ 171.1021, found 171.1028.

The allylic alcohol 10. To a solution of the aldehyde **4** (100 mg, 581 μmol, 1.0 equiv) in dry DMF (1.5 mL) were added a solution of the vinyl iodide **3** (412 mg, 1.16 mmol, 2.0 equiv) in dry DMF (1.0 mL), CrCl₂ (285 mg, 2.32 mmol, 4.0 equiv) and NiCl₂ (15.0 mg, 116 μmol, 0.20 equiv) at room temperature under an argon atmosphere. After being stirred at the same temperature for 4 h, the reaction mixture was quenched with saturated aqueous NH₄Cl. The organic layer was separated, and the aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over MgSO₄, and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by chromatography on silica gel (eluted with *n*-hexane/EtOAc = 6:1) to afford the allylic alcohol **10** (180 mg, 449 μmol, 77%) as a colorless oil. The spectral data of the synthetic **10** were in good agreement with those of reported.⁵⁵ ¹H NMR (400 MHz, CDCl₃, 1:1 diastereomer mixture) δ 5.59–5.70 (m, 1H), 5.41–5.48 (m, 1H), 3.80–4.00 (m, 3H), 3.42–3.47 (m, 1H), 2.29–2.36 (m, 1H), 2.06 (s, 1.5H), 2.05 (s, 1.5H), 1.86–1.96 (m, 1H), 1.64–1.75 (m, 1H), 1.33–1.54 (m, 4H), 0.84–1.05 (m, 22H), 0.038–0.043 (m, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃, 1:1 diastereomer mixture) δ 171.20,



171.17, 135.8, 135.5, 130.7, 129.8, 77.1, 76.9, 76.5, 69.0, 41.2, 36.8, 36.7, 36.20, 36.19, 30.02, 30.0, 26.5, 26.4, 25.9, 20.9, 18.2, 18.1, 15.8, 15.5, 15.0, 9.4, 9.2, -4.3, -4.36, -4.45, -4.48; IR (neat) 3463, 2959, 2931, 2857, 1741, 1251, 1017, 836, 774 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{22}\text{H}_{44}\text{O}_4\text{SiNa}$ $[\text{M} + \text{Na}]^+$ 423.2901, found 423.2889.

The TBS ether 11a. To a solution of the alcohol **10** (193 mg, 480 μmol , 1.0 equiv) in dry CH_2Cl_2 (5.0 mL) were added 2,6-lutidine (111 μL , 960 μmol , 2.0 equiv) and TBSOTf (221 μL , 960 μmol , 2.0 equiv) at 0 $^\circ\text{C}$ under an argon atmosphere. After being stirred at the same temperature for 1.5 h, the reaction mixture was quenched with saturated aqueous NaHCO_3 . The organic layer was separated, and the aqueous layer was extracted twice with CH_2Cl_2 . The combined organic layers were washed with saturated aqueous NaHCO_3 and brine, dried over MgSO_4 , and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 15 : 1) to afford the TBS ether **11a** (233 mg, 450 μmol , 94%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.56 (dd, 0.5H, J = 15.5, 7.7 Hz), 5.32–5.48 (m, 1.5H), 3.94–3.99 (m, 1H), 3.84–3.88 (m, 1H), 3.76–3.81 (m, 1H), 3.39–3.45 (m, 1H), 2.26–2.33 (m, 1H), 2.04 (s, 3H), 1.83–1.92 (m, 1H), 1.37–1.65 (m, 4H), 0.83–0.97 (m, 31H), -0.01–0.04 (m, 12H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 171.3, 134.0, 131.4, 130.3, 77.5, 77.14, 77.09, 69.2, 69.1, 41.5, 41.3, 37.32, 37.29, 36.64, 36.58, 30.0, 26.51, 26.48, 25.94, 25.90, 21.0, 20.9, 18.19, 18.17, 18.11, 16.6, 16.5, 15.6, 15.5, 9.1, 9.0, -3.9, -4.1, -4.3, -4.4, -4.5, -4.8, -4.9; IR (neat) 2958, 2930, 2886, 2857, 1744, 1251, 1064, 1018, 836, 774 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{28}\text{H}_{58}\text{O}_4\text{Si}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 537.3766, found 537.3762.

The TES ether 11b. Compound **11b** was prepared from the alcohol **10** (164 mg, 409 μmol) according to the procedure above described for **11a** (TESOTf was used instead of TBSOTf), and was obtained in an 88% yield (185 mg, 359 μmol) as a colorless oil after purification by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 15 : 1). ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.56 (dd, 0.5H, J = 15.9, 7.3 Hz), 5.33–5.48 (m, 1.5H), 3.94–3.99 (m, 1H), 3.76–3.88 (m, 2H), 3.39–3.45 (m, 1H), 2.26–2.33 (m, 1H), 2.05 (s, 1.5H), 2.04 (s, 1.5H), 1.83–1.93 (m, 1H), 1.58–1.66 (m, 1H), 1.35–1.54 (m, 3H), 0.83–0.97 (m, 31H), 0.56 (q, 6H, J = 7.9 Hz), 0.05 (s, 3H), 0.04 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 171.1, 134.1, 131.2, 130.2, 77.8, 77.2, 77.1, 69.14, 69.11, 41.5, 41.2, 37.4, 37.3, 36.5, 30.1, 30.0, 26.50, 26.48, 25.9, 20.9, 18.2, 18.1, 16.3, 15.7, 15.5, 9.2, 9.0, 6.9, 5.1, 5.0, -4.3, -4.49, -4.53; IR (neat) 2957, 2876, 1743, 1061, 1015, 835, 742 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{28}\text{H}_{58}\text{O}_4\text{Si}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 537.3766, found 537.3755.

The alcohol 12a. To a solution of the acetate **11a** (321 mg, 623 μmol , 1.0 equiv) in dry CH_3OH (1.3 mL) was added K_2CO_3 (103 mg, 750 μmol , 1.2 equiv) at room temperature under an argon atmosphere. After being stirred at the same temperature for 5 h, the reaction mixture was diluted with CH_2Cl_2 and water. The organic layer was separated, and the aqueous layer was extracted twice with CH_2Cl_2 . The combined organic layers were washed with brine, dried over MgSO_4 , and filtered. The filtrate

was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 10 : 1) to afford the alcohol **12a** (237 mg, 620 μmol , 93%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.54 (dd, 0.5H, J = 15.8, 7.6 Hz), 5.31–5.47 (m, 1.5H), 3.84–3.88 (m, 1H), 3.49–3.53 (m, 1H), 3.33–3.43 (m, 2H), 2.26–2.33 (m, 1H), 1.36–1.73 (m, 5H), 0.83–0.97 (m, 31H), 0.00–0.04 (m, 12H) (one proton (OH) was not observed); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 134.1, 133.9, 131.2, 130.3, 77.9, 77.3, 77.2, 77.1, 68.0, 67.8, 41.6, 41.3, 37.44, 37.43, 36.5, 36.0, 33.23, 33.20, 26.4, 26.3, 25.93, 25.91, 18.20, 18.18, 18.0, 17.9, 16.63, 16.58, 16.1, 16.0, 9.1, -3.9, -4.1, -4.31, -4.33, -4.4, -4.5, -4.79, -4.82; IR (neat) 3343, 2957, 2929, 2857, 1463, 1254, 1064, 1018, 835, 773 cm^{-1} ; HRMS [ESI] m/z calcd for $\text{C}_{26}\text{H}_{56}\text{O}_3\text{Si}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 495.3660, found 495.3648.

The alcohol 12b. Compound **12b** was prepared from the acetate **11b** (460 mg, 894 μmol) according to the procedure above described for **12a**, and was obtained in a 77% yield (328 mg, 693 μmol) as a colorless oil after purification by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 10 : 1). ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.57 (dd, 0.5H, J = 15.8, 7.4 Hz), 5.33–5.49 (m, 1.5H), 3.83–3.87 (m, 1H), 3.38–3.53 (m, 3H), 2.27–2.34 (m, 1H), 1.34–1.75 (m, 5H), 0.83–0.98 (m, 31H), 0.56 (q, 6H, J = 7.8 Hz), 0.05 (s, 3H), 0.04 (s, 3H) (one proton (OH) was not observed); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 134.3, 134.2, 130.9, 130.3, 78.2, 77.6, 77.1, 67.9, 67.6, 41.7, 41.2, 37.54, 37.47, 36.9, 35.8, 33.4, 33.3, 26.4, 26.3, 25.92, 25.91, 18.22, 18.15, 18.0, 16.53, 16.48, 16.3, 16.1, 9.3, 9.1, 6.9, 5.02, 4.99, -4.3, -4.46, -4.52; IR (neat) 3351, 2957, 2931, 1462, 1254, 1064, 1016, 836, 773 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{26}\text{H}_{56}\text{O}_3\text{Si}_2\text{Na}$ $[\text{M} + \text{Na}]^+$ 495.3660, found 495.3647.

The carboxylic acid 2a. To a solution of the alcohol **12a** (220 mg, 470 μmol , 1.0 equiv) in dry CH_2Cl_2 (9.0 mL) were added NaHCO_3 (118 mg, 1.41 mmol, 3.0 equiv) and Dess–Martin periodinane (260 mg, 610 μmol , 1.3 equiv) at room temperature under an argon atmosphere. After being stirred at the same temperature for 1 h, the reaction mixture was quenched with 20% aqueous $\text{Na}_2\text{S}_2\text{O}_3$. The organic layer was separated, and the aqueous layer was extracted twice with CH_2Cl_2 . The combined organic layers were washed with saturated aqueous NaHCO_3 and brine, dried over MgSO_4 , and filtered. The filtrate was concentrated *in vacuo*, and the resulting crude aldehyde was used for the next reaction without further purification.

To a solution of the crude aldehyde in *tert*-BuOH (4.0 mL) and water (4.0 mL) were added 2-methyl-2-butene (1.2 mL, 11.3 mmol, 30 equiv), NaClO_2 (102 mg, 1.13 mmol, 3.0 equiv) and NaH_2PO_4 (136 mg, 1.13 mmol, 3.0 equiv) at 0 $^\circ\text{C}$ under an argon atmosphere. After being stirred at room temperature for 2 h, the reaction mixture was diluted with EtOAc. The organic layer was separated, and the aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 6 : 1) to afford the carboxylic acid **2a** (165 mg, 340



μmol , 72% in 2 steps) as a colorless oil. ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.55 (dd, 0.5H, $J = 15.6$, 7.6 Hz), 5.48 (dd, 0.5H, $J = 15.6$, 7.8 Hz), 5.33–5.40 (m, 1H), 3.84–3.90 (m, 1H), 3.42 (quin, 1H, $J = 5.4$ Hz), 2.51–2.63 (m, 1H), 2.25–2.34 (m, 1H), 1.82–1.92 (m, 1H), 1.55–1.64 (m, 1H), 1.36–1.49 (m, 2H), 1.19 (d, 1.5H, $J = 6.8$ Hz), 1.18 (d, 1.5H, $J = 7.1$ Hz), 1.06–1.14 (m, 1H), 0.83–0.97 (m, 27H), -0.01 – 0.04 (m, 12H) (one proton (COOH) was not observed); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 183.0, 182.9, 134.3, 134.1, 130.9, 130.2, 77.9, 77.4, 77.1, 41.5, 41.3, 37.9, 37.7, 37.4, 37.2, 36.9, 36.7, 26.53, 26.49, 25.91, 25.88, 18.20, 18.18, 18.14, 18.0, 16.54, 16.47, 15.2, 15.1, 9.1, 9.0, -4.0 , -4.2 , -4.3 , -4.4 , -4.5 , -4.88 , -4.90 ; IR (neat) 2958, 2929, 2857, 1708, 1462, 1254, 1062, 835, 773 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{26}\text{H}_{54}\text{O}_4\text{Si}_2\text{Na}$ [$M + \text{Na}$] $^+$ 509.3453, found 509.3448.

The carboxylic acid 2b. Compound **2b** was prepared from the alcohol **12b** (328 mg, 693 μmol) according to the procedure above described for **2a**, and was obtained in a 75% yield (252 mg, 518 μmol) in 2 steps as a colorless oil after purification by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 6 : 1). ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.57 (dd, 0.5H, $J = 15.6$, 7.6 Hz), 5.33–5.50 (m, 1.5H), 3.83–3.89 (m, 1H), 3.40–3.45 (m, 1H), 2.53–2.63 (m, 1H), 2.27–2.33 (m, 1H), 1.82–1.92 (m, 1H), 1.55–1.63 (m, 1H), 1.34–1.48 (m, 2H), 1.19 (d, 1.5H, $J = 6.8$ Hz), 1.18 (d, 1.5H, $J = 7.1$ Hz), 1.06–1.13 (m, 1H), 0.83–0.97 (m, 27H), 0.56 (q, 6H, $J = 8.2$ Hz), 0.05 (s, 3H), 0.04 (s, 3H) (one proton (COOH) was not observed); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 183.0, 182.9, 134.4, 134.2, 130.8, 130.4, 78.0, 77.5, 77.1, 41.5, 41.2, 37.9, 37.8, 37.4, 37.3, 36.9, 36.7, 26.5, 25.9, 18.2, 18.12, 18.05, 16.4, 16.3, 15.3, 15.0, 9.2, 9.0, 6.9, 5.01, 5.00, -4.3 , -4.45 , -4.50 ; IR (neat) 2958, 2934, 2877, 1709, 1463, 1254, 1064, 1015, 835 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{26}\text{H}_{54}\text{O}_4\text{Si}_2\text{Na}$ [$M + \text{Na}$] $^+$ 509.3453, found 509.3450.

The thioester 13a. To a solution of the carboxylic acid **2a** (147 mg, 300 μmol , 1.0 equiv) in dry CH_2Cl_2 (2.0 mL) were added *N*-(2-mercaptoethyl)acetamide (43.3 mg, 363 μmol , 1.2 equiv), EDCI-HCl (116 mg, 610 μmol , 2.0 equiv) and DMAP (4.1 mg, 33.8 μmol , 0.10 equiv) at 0 $^\circ\text{C}$ under an argon atmosphere. After being stirred at the same temperature for 3.5 h, the reaction mixture was quenched with water. The organic layer was separated, and the aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with brine, dried over MgSO_4 , and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 2 : 1) to afford the thioester **13a** (150 mg, 256 μmol , 84%) as a colorless oil. ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.78 (brs, 1H), 5.55 (dd, 0.5H, $J = 15.5$, 7.7 Hz), 5.47 (dd, 0.5H, $J = 15.4$, 7.6 Hz), 5.30–5.38 (m, 1H), 3.83–3.86 (m, 1H), 3.40–3.45 (m, 3H), 2.98–3.05 (m, 2H), 2.76–2.86 (m, 1H), 2.26–2.34 (m, 1H), 1.84–1.96 (m, 4H), 1.38–1.54 (m, 3H), 1.18 (d, 1.5H, $J = 6.8$ Hz), 1.17 (d, 1.5H, $J = 7.1$ Hz), 1.05–1.14 (m, 1H), 0.83–0.97 (m, 27H), -0.01 – 0.05 (m, 12H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 204.4, 170.1, 134.34, 134.27, 130.8, 130.1, 77.7, 77.4, 77.1, 46.5, 46.4, 41.5, 41.3, 39.89, 39.87, 37.7, 37.5, 37.3, 37.2, 28.1, 26.5, 26.4, 25.92, 25.89, 23.2, 19.0, 18.8, 18.2,

18.1, 16.5, 16.4, 15.3, 15.2, 9.14, 9.09, -3.9 , -4.1 , -4.31 , -4.33 , -4.4 , -4.5 , -4.8 , -4.9 ; IR (neat) 3285, 2957, 2930, 2857, 1691, 1657, 1462, 1254, 1062, 836, 774 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{30}\text{H}_{61}\text{NO}_4\text{SSi}_2\text{Na}$ [$M + \text{Na}$] $^+$ 610.3752, found 610.3741.

The thioester 13b. Compound **13b** was prepared from the carboxylic acid **2b** (252 mg, 518 μmol) according to the procedure above described for **13a**, and was obtained in a 77% yield (233 mg, 397 μmol) as a colorless oil after purification by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 2 : 1). ^1H NMR (400 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 5.79 (brs, 1H), 5.56 (dd, 0.5H, $J = 15.6$, 7.6 Hz), 5.47 (dd, 0.5H, $J = 15.7$, 7.7 Hz), 5.30–5.39 (m, 1H), 3.81–3.85 (m, 1H), 3.40–3.45 (m, 3H), 2.96–3.05 (m, 2H), 2.77–2.87 (m, 1H), 2.27–2.33 (m, 1H), 1.88–1.96 (m, 4H), 1.34–1.56 (m, 3H), 1.18 (d, 1.5H, $J = 6.6$ Hz), 1.17 (d, 1.5H, $J = 6.8$ Hz), 1.05–1.12 (m, 1H), 0.83–0.97 (m, 27H), 0.56 (q, 6H, $J = 8.1$ Hz), 0.05 (s, 3H), 0.04 (s, 3H); $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3 , 1 : 1 diastereomer mixture) δ 204.34, 204.32, 170.2, 134.4, 134.3, 130.6, 129.9, 77.8, 77.4, 46.42, 46.36, 41.4, 41.1, 39.79, 39.77, 37.6, 37.5, 37.4, 37.1, 28.03, 28.02, 26.4, 25.9, 23.1, 18.9, 18.7, 18.1, 16.3, 16.2, 15.3, 15.1, 9.2, 9.0, 6.8, 5.0, 4.9, -4.4 , -4.5 , -4.6 ; IR (neat) 3290, 2957, 2876, 2857, 1691, 1656, 1461, 1254, 1102, 1061, 1015, 970, 836, 742 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{30}\text{H}_{61}\text{NO}_4\text{SSi}_2\text{Na}$ [$M + \text{Na}$] $^+$ 610.3752, found 610.3735.

The lactone 15a. To a solution of the TBS ether **13a** (40.6 mg, 69.0 μmol , 1.0 equiv) in dry CH_3CN (2.0 mL) were added pyridine (55.6 μL , 690 μmol , 10 equiv) and HF·pyridine (373 μL , 4.14 mmol, 60 equiv) at 0 $^\circ\text{C}$ under an argon atmosphere. After being stirred at room temperature for 14 h, the reaction mixture was quenched with saturated aqueous NaHCO_3 , and diluted with EtOAc. The organic layer was separated, and the aqueous layer was extracted three times with EtOAc. The combined organic layers were washed with saturated aqueous CuSO_4 and brine, dried over MgSO_4 , and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by column chromatography on silica gel (eluted with *n*-hexane/EtOAc = 2 : 1) to afford the lactone **15a** (7.9 mg, 33.0 μmol , 48%) as a colorless oil. $[\alpha]_{\text{D}}^{22} -14$ (c 0.68, CHCl_3); ^1H NMR (600 MHz, CDCl_3) δ 5.74 (dd, 1H, $J = 15.5$, 7.7 Hz), 5.47 (dd, 1H, $J = 15.5$, 8.0 Hz), 4.28 (dd, 1H, $J = 10.3$, 8.0 Hz), 3.40–3.43 (m, 1H), 2.50–2.57 (m, 1H), 2.29–2.35 (m, 1H), 1.97 (ddd, 1H, $J = 13.4$, 6.2, 3.3 Hz), 1.76–1.83 (m, 1H), 1.52–1.59 (m, 1H), 1.34–1.41 (m, 2H), 1.29 (d, 3H, $J = 7.1$ Hz), 1.04 (d, 3H, $J = 6.7$ Hz), 0.96 (t, 3H, $J = 7.4$ Hz), 0.94 (d, 3H, $J = 6.7$ Hz) (one proton (OH) was not observed); $^{13}\text{C}\{^1\text{H}\}$ NMR (150 MHz, CDCl_3) δ 174.1, 138.6, 127.9, 88.3, 76.3, 42.0, 37.3, 36.3, 34.2, 27.1, 17.2, 14.7, 10.3; IR (neat) 3447, 2963, 2933, 2876, 1729, 1458, 1207, 1167, 1089, 1004, 974 cm^{-1} ; HRMS[ESI] m/z calcd for $\text{C}_{14}\text{H}_{24}\text{O}_3\text{Na}$ [$M + \text{Na}$] $^+$ 263.1618, found 263.1615.

The enone 1a. To a solution of **13b** (108 mg, 184 μmol , 1.0 equiv) in dry DMSO (3.0 mL) was added 2-iodoxybenzoic acid (IBX; 169 mg, 552 μmol , 3.0 equiv) at room temperature under an argon atmosphere. After being stirred at 80 $^\circ\text{C}$ for 3.5 h, the reaction mixture was diluted with Et_2O and water. The organic layer was separated, and the aqueous layer was extracted four times with diethyl ether. The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered. The filtrate was



concentrated *in vacuo*, and the resulting crude enone was used for the next reaction without further purification.

To a solution of the crude enone in dry CH₃CN (1.6 mL) was added 55% aqueous HF (0.8 mL) at 0 °C under an argon atmosphere. After being stirred at room temperature for 30 min, the reaction mixture was diluted with CH₂Cl₂, and quenched with saturated aqueous NaHCO₃. The organic layer was separated, and the aqueous layer was extracted twice with CH₂Cl₂. The combined organic layers were washed with saturated aqueous brine, dried over Na₂SO₄, and filtered. The filtrate was concentrated *in vacuo*, and the resulting residue was purified by chromatography on silica gel (eluted with *n*-hexane/EtOAc = 1 : 7) to afford the alcohol **1a** (54.0 mg, 151 μmol, 82% in 2 steps) as a colorless oil. The spectral data of the synthetic **1a** were in good agreement with those of reported.²⁷ [α]_D²⁰ +31 (c 1.0, CH₃OH) [lit. [α]_D²⁰ +36.5 (c 0.203, CH₃OH)]; ¹H NMR (600 MHz, CDCl₃) δ 6.90 (dd, 1H, *J* = 16.0, 7.5 Hz), 6.16 (dd, 1H, *J* = 16.0, 0.9 Hz), 5.96 (brs, 1H), 3.53–3.56 (m, 1H), 3.45–3.51 (m, 1H), 3.38–3.43 (m, 1H), 2.98–3.06 (m, 2H), 2.80–2.84 (m, 1H), 2.71–2.76 (m, 1H), 2.45–2.50 (m, 1H), 2.13–2.18 (m, 1H), 1.98 (s, 3H), 1.92 (brd, 1H, *J* = 4.4 Hz), 1.50–1.56 (m, 1H), 1.38–1.47 (m, 2H), 1.18 (d, 3H, *J* = 6.9 Hz), 1.12 (d, 3H, *J* = 6.9 Hz), 1.10 (d, 3H, *J* = 6.9 Hz), 0.99 (t, 3H, *J* = 7.3 Hz); ¹³C{¹H} NMR (150 MHz, CDCl₃) δ 204.0, 202.8, 170.3, 150.1, 128.3, 75.8, 46.7, 42.2, 41.5, 39.4, 37.2, 28.5, 27.3, 23.2, 18.6, 16.9, 13.5, 10.4; IR (neat) 3309, 2969, 2933, 1686, 1660, 970 cm⁻¹; HRMS[ESI] *m/z* calcd for C₁₈H₃₁NO₄SNa [M + Na]⁺ 380.1866 found 380.1859.

Vector construction, protein expression, and purification

A recombinant plasmid pKU518pkmyP1_G14 containing entire gene cluster for pikromycin biosynthesis was selected from our BAC library of pikromycin-producing *Streptomyces* sp. AM4900 which was prepared by the same methods as described previously.⁵⁶ Domain annotation was performed based on amino acid alignment by referred by previously works.^{10,57,58} Then, an expression vector of pHis10C-PikAIII-M5-TE (Fig. S2) containing PikAIII module 5 and thioesterase (TE) domain from module 6 were constructed as follows. Both coding regions were amplified by PCR using pKU518pkmyP1_G14 and primer sets (Table S1). Assembled gene encoding pikAIII (4.7 kb) and TE domain (1 kb) from pikAIV were cloned into the pET28b(+)vector, in which the C-terminal hexa-histidine tag was modified to deca-histidine tag (pHis10C vector). The expression vectors were introduced into NEB 10 β Competent *E. coli*. The resulting transformants were selected on LB-Miller agar plate containing 50 μg mL⁻¹ kanamycin at 37 °C for 12 h. The transformants were further cultured on LB-Miller medium containing 50 μg mL⁻¹ kanamycin at 37 °C for 12 h. After plasmid isolation, the sequences of pHis10C-PikAIII-M5-TE were confirmed by sequencing.

For *in vivo* phosphopantetheinylation of acyl carrier protein (ACP) domains on recombinant modular enzymes, pHis10C-PikAIII-M5-TE was co-expressed in *E. coli* with phosphopantetheinyl transferase *pptA2* (*sav1748*) gene from *Streptomyces avermitilis*.⁵⁹ Expression vector of the *pptA2* gene was constructed as follows. The codon optimized *pptA2* gene was prepared for efficient expression in *E. coli* (Integrated DNA

Technologies Inc., Coralville, IA). Then, the *pptA2* gene was cloned into NcoI and HindIII sites of pACYCDuet-1 vector.

Both pACYC-*pptA2* and pHis10C-PikAIII-M5-TE vectors were used to transform Invitrogen™ One Shot™ BL21 Star™ (DE3) Chemically Competent *E. coli*. The resulting transformants were cultured on LB-Miller agar plate containing 50 μg mL⁻¹ kanamycin and 34 μg mL⁻¹ chloramphenicol at 37 °C for 16 h. The transformant was inoculated into 30 mL (15 mL × 6) of LB-Miller medium containing 50 μg mL⁻¹ kanamycin and 34 μg mL⁻¹ chloramphenicol and cultured at 28 °C overnight (final OD₆₀₀ = 3.0). Then, overnight seed culture was inoculated into 900 mL (150 mL × 6) LB-Miller medium containing 25 μg mL⁻¹ kanamycin and 34 μg mL⁻¹ chloramphenicol (initial OD₆₀₀ = 0.04), and cultured at 28 °C for 5 h until OD₆₀₀ = 1.0 was achieved. Cooling of cell culture flasks in an ice bath (1 h) was followed by addition of 0.1 mM IPTG and cultured at 18 °C for 16 h. Cells were harvested by centrifugation at 4000×*g* at 4 °C for 20 min using an Allegra X-15R Benchtop Centrifuge (Beckman Coulter), and were suspended in 90 mL lysis buffer (50 mM HEPES-NaOH (pH 7.5) containing 10% [v/v] glycerol and 300 mM NaCl). Then, cell suspension containing 10 mM MgCl₂ and 20 U mL⁻¹ Cryonase Cold-active Nuclease (Takara Bio Inc.) was sonicated using BIORUPTOR 2 (Sonicbio Co., Ltd, Kanagawa, Japan) for 1 h (30 s on/30 s off, 60 cycles) on ice chilled water, and centrifuged at 20 000×*g* at 4 °C for 30 min using an Sorvall Legend XFR (Thermo Fisher). The cleared lysate was applied to a chromatography system, BioLogic LP System + Model 2110 fraction collector (Bio-RAD) equipped with HisTrap HP (5 mL, Cytiva) for affinity purification under the following system at 4 °C. A, 200 mM potassium phosphate buffer (pH 7.5) containing 10% [v/v] glycerol; B, 200 mM potassium phosphate buffer (pH7.5) containing 10% [v/v] glycerol and 500 mM imidazole; C, lysis buffer. Column equilibrating, sample loading, and elution procedure were as follows. 100% C for 25 min (10 CV), loading of cleared lysate for 45 min (20 CV), 100% C for 25 min (10 CV), 5% B (95% A) for 25 min, 5% to 100% B (95% to 0% A) over 50 min, 100% B for 25 min; flow rate, 2 mL min⁻¹ (Fig. S4).

Expression vector of reductive loop exchanged module enzymes, PikAIII-M5ΔKR5::DH2-KR2-TE was constructed as follows. Full length DNA of PikAIII-M5ΔKR5::DH2-KR2 gene sequence (Fig. S2) was obtained by artificial gene synthesis (Integrated DNA Technologies). Then, the PikAIII-M5ΔKR5::DH2-KR2 fragment was amplified by PCR using primer set (Table S1). TE domain from PikAIV module 6 was also amplified by PCR using primer set (Table S1) and template (pKU518pkmyP1_G14). These amplicons were assembled into NdeI and XhoI sites of the pET28b(+) modified vector (The C-terminal hexa-histidine tag coding region was modified to deca-histidine tag) by seamless cloning method using Gibson assemble master mix. Then, the assembled DNA was introduced into NEB 10 β Competent *E. coli*. The transformants were grown on LB-Miller agar plate supplemented with 50 μg mL⁻¹ kanamycin for 12 h at 37 °C and colonies were selected by colony directed PCR. The positive transformants were further grown in LB-Miller liquid medium supplemented with 50 μg mL⁻¹ kanamycin for 12 h at 37 °C. The plasmids were recovered from the transformants by using QIAprep Spin Miniprep Kit and the inserted DNA sequences were verified by sequencing, obtaining pHis10C-PikAIII-M5ΔKR5::DH2-KR2-TE. For *in vivo*



phosphopantetheinylation of ACP domains on recombinant module enzymes, the expression vectors for the module enzymes were co-expressed with phosphopantetheinyl transferase by the same expression system of PikAIII-M5-TE.

For coupling reaction in preparation of NMR samples, *E. coli* recombinant protein of malonyl-CoA ligases (MatB)⁶⁰ were prepared template DNA of *matB* gene sequence was obtained by artificial gene synthesis with codon optimization for *E. coli* expression (GENEWIZ). The artificially synthesized DNA of *matB* gene were amplified by PCR using specific primer set as shown in Table S1. The amplified DNA fragment assembled into NdeI and HindIII sites of the pET28b(+) modified vector pHis8 (ref. 61) (the N-terminal hexa-histidine tag coding region was modified to octa-histidine tag) by seamless cloning method using In-Fusion method. After that, expression plasmid was constructed by same method to pACYC-*pptA2* vector, excepting 50 $\mu\text{g mL}^{-1}$ kanamycin was used as a selection marker in all cultivation steps, to obtain pHis8-*matB*. Excepting no co-expression with *pptA2* gene, MatB recombinant protein were prepared by the same method for the module enzymes (Fig. S5).

Enzymatic reaction and UPLC-MS analysis of reaction product

A 25 μL reaction mixture (50 mM sodium phosphate buffer (pH 7.2) containing 400 mM citric acid, 10 mM NADPH, 7.5 mM methylmalonyl-NAC (**16**), 5 mM the NAC thioester **1a**, and 42.7 nM PikAIII-M5-TE) were incubated at 25 °C for 72 h. Then, the reaction was quenched by addition of CH_3CN (50% [v/v], final) and the mixture was centrifuged at 4 °C for 30 min. The samples (1 μL) was analyzed by UPLC (ACQUITY UPLC H-Class PLUS, Waters)-MS (QDa, Waters) system under the following conditions: mobile phase (A, water containing 0.1% formic acid; B, acetonitrile containing 0.1% formic acid), 5% B for 1 min, 5% to 100% B over 5 min, 100% B for 1 min, 100% to 5% B over 1 min; flow rate, 0.5 mL min^{-1} , column; ACQUITY UPLC BEC C18 1.7 μm (Waters), column temperature; 40 °C.

Substrate septicity analysis of primer substrate for PikAIII-M5-TE and PikAIII-M5- $\Delta\text{KR5::DH2-KR2-TE}$ was performed as follows: 12.5 μL reaction mixture (50 mM HEPES-NaOH (pH 7.5) containing 10% [v/v] glycerol, 300 mM NaCl, 1 mM NADPH, 1 mM methylmalonyl-CoA, and 1 mM primer substrates) was incubated for 1 h (2 nM PikAIII-M5-TE) or 12 h (28 nM PikAIII-M5- $\Delta\text{KR5::DH2-KR2-TE}$) at 25 °C. Then the mixture was acidified by an addition of hydrochloric acid (2 M, final) followed by extraction with equal volumes of ethyl acetate (3 times). Ethyl acetate phases were evaporated and dissolved in 100 μL methanol. After filtration, 4 μL of the sample was analyzed by UPLC (ACQUITY UPLC H-Class PLUS, Waters) -MS (API3200, AB Sciex) system under the following conditions: mobile phase (A, water containing 0.05% formic acid, B, acetonitrile), 5% B for 1 min, 5% to 100% B over 5 min, 100% B for 1 min, 100% to 5% B over 1 min; flow rate, 0.5 mL/min.

Enzyme reaction and isolation of reaction products for structure analysis

To determine the chemical structure of PikAIII-M5-TE reaction product, a total of 2.5 mL of the reaction (50 mM sodium

phosphate buffer (pH 7.2) containing 400 mM citric acid, 10 mM NADPH, 7.5 mM methylmalonyl-NAC (**16**), 5 mM the NAC thioester **1a**, and 42.7 nM PikAIII-M5-TE) was performed. Then, the 2.5 mL aqueous layer was extracted three times with 7.5 mL ethyl acetate. The organic layer was separated and dried under nitrogen flow. Then, 10 mL CH_3OH were added to the residues, and the solution was analyzed by HPLC (2535 Quaternary Gradient Module, Waters) equipped with photodiode array detector (2998 Modular LC photodiode array detector, Waters) under the following conditions: elution rate, acetonitrile/water = 7:3 (isocratic); flow rate, 4 mL min; column, Pegasil ODS SP100 10 Φ \times 250 mm (Senshu Scientific Co. Ltd, Tokyo, Japan); column temperature, 20 °C (room temperature). A peak of 6.2 min was collected and the solvent was evaporated by a rotary evaporator to afford 10-deoxymethynolide (**17**). The spectral data of the synthetic compound **17** were in good agreement with those of reported.⁴⁶ ¹H NMR (600 MHz, CDCl_3) δ 6.74 (dd, 1H, $J = 15.9, 5.5$ Hz), 6.74 (dd, 1H, $J = 15.9, 1.9$ Hz), 5.01 (dd, 1H, $J = 9.2, 6.1, 2.9$ Hz), 3.56 (d, 1H, $J = 10.5$ Hz), 2.56–2.66 (m, 2H), 2.50–2.55 (m, 1H), 1.62–1.73 (m, 4H), 1.25–1.35 (m, 5H), 1.22 (d, 3H, $J = 7.0$ Hz), 1.12 (d, 3H, $J = 7.0$ Hz), 1.00 (d, 3H, $J = 6.5$ Hz), 0.91 (t, 3H, $J = 7.6$ Hz); ¹³C{¹H} NMR (150 MHz, CDCl_3) δ 204.9, 174.7, 147.1, 125.7, 78.3, 73.7, 45.2, 43.4, 38.0, 33.24, 33.21, 25.2, 17.7, 17.4, 16.4, 10.3, 9.6.

Enzymatic reaction products **18b** were prepared as follows. 15 mL enzyme reaction mixture (10% [v/v] glycerol, 50 mM potassium phosphate buffer (pH 7.2), 250 mM citrate buffer (pH 7.2), 3 mM NADPH, 4 mM methylmalonate, 4 mM ATP, 0.5 mM coenzyme A, 10 mM MgCl_2 , 2.5 mM TCEP, 3.08 μM MatB, 2 mM **1b**, and 2.18 μM PikAIII-M5- $\Delta\text{KR5::DH2-KR2-TE}$) were incubated for 18 h at 25 °C. Each reaction mixture was directly applied to an ODS column and washed thoroughly with ultrapure water. Then, the bound products were eluted with 100% acetonitrile. The eluents were evaporated *in vacuo* and dissolved in methanol.

Author contributions

E. Okamura, K. Ohsawa, H. Ban, Y. Sugiyama, and J. Hashimoto carried out the experiments, analyzed the data. E. Okamura and K. Ohsawa wrote the original manuscript. K. Kudo, M. Yoshida, K. Shin-ya, and H. Ikeda analyzed the data and participated in the discussion. K. Shin-ya and H. Ikeda guided the project and edited the manuscript. S. Takahashi and T. Doi supervised the whole project & guided writing, reviewed, and edited the manuscript.

Conflicts of interest

The authors declare no conflict of interest.

Data availability

Reasonable requests for additional information can be made to the corresponding authors.

Supplementary information (SI): ¹H and ¹³C NMR spectra and additional experimental data. See DOI: <https://doi.org/10.1039/d5sc07470c>.



Acknowledgements

This study was supported by the Japan Agency for Medical Research and Development (AMED), Grant Number JP20ae0101045, MEXT Grant-in-Aid for Transformative Research Areas (A) Digitalization-driven Transformative Organic Synthesis (Digi-TOS), Grant Number JP24H01055, JSPS KAKENHI Grant-in-Aid for Scientific Research(C), Grant Number 25K08901, and MEXT Grant-in-Aid for Transformative Research Areas (A), Grant Number, 25H01597.

References

- 1 S. E. Rossiter, M. H. Fletcher and W. M. Wuest, *Chem. Rev.*, 2017, **117**, 12415–12474.
- 2 K. J. Weissman and P. F. Leadlay, *Nat. Rev. Microbiol.*, 2005, **3**, 925–936.
- 3 A. A. Koch, J. J. Schmidt, A. N. Lowell, D. A. Hansen, K. M. Coburn, J. A. Chemler and D. H. Sherman, *Angew Chem. Int. Ed. Engl.*, 2020, **59**, 13575–13580.
- 4 A. R. Narayan, G. Jimenez-Oses, P. Liu, S. Negretti, W. Zhao, M. M. Gilbert, R. O. Ramabhadran, Y. F. Yang, L. R. Furan, Z. Li, L. M. Podust, J. Montgomery, K. N. Houk and D. H. Sherman, *Nat. Chem.*, 2015, **7**, 653–660.
- 5 M. Klaus and M. Grininger, *Nat. Prod. Rep.*, 2018, **35**, 1070–1081.
- 6 H. Brockmann and W. Henkel, *Naturwissenschaften*, 1950, **37**, 138–139.
- 7 H. Brockmann and W. Henkel, *Chem. Ber.*, 1951, **84**, 284–288.
- 8 Y. Xue, L. Zhao, H. W. Liu and D. H. Sherman, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 12111–12116.
- 9 J. D. Kittendorf and D. H. Sherman, *Bioorg. Med. Chem.*, 2009, **17**, 2137–2146.
- 10 S. Dutta, J. R. Whicher, D. A. Hansen, W. A. Hale, J. A. Chemler, G. R. Congdon, A. R. Narayan, K. Hakansson, D. H. Sherman, J. L. Smith and G. Skiniotis, *Nature*, 2014, **510**, 512–517.
- 11 D. A. Hansen, A. A. Koch and D. H. Sherman, *J. Am. Chem. Soc.*, 2017, **139**, 13450–13455.
- 12 Y. Yin, H. Lu, C. Khosla and D. E. Cane, *J. Am. Chem. Soc.*, 2003, **125**, 5671–5676.
- 13 J. F. Barajas, J. M. Blake-Hedges, C. B. Bailey, S. Curran and J. D. Keasling, *Synth. Syst. Biotechnol.*, 2017, **2**, 147–166.
- 14 K. J. Weissman, *Beilstein J. Org. Chem.*, 2017, **13**, 348–371.
- 15 A. T. Keatinge-Clay, *Nat. Prod. Rep.*, 2016, **33**, 141–149.
- 16 A. T. Keatinge-Clay, *Nat. Prod. Rep.*, 2012, **29**, 1050–1073.
- 17 P. Caffrey, *ChemBioChem*, 2003, **4**, 654–657.
- 18 C. Liu, M. Yuan, X. Xu, L. Wang, E. A. T. Keatinge-Clay, Z. Deng, S. Lin and J. Zheng, *J. Struct. Biol.*, 2018, **203**, 135–141.
- 19 E. E. Drufva, N. R. Spengler, E. G. Hix and C. B. Bailey, *ChemBioChem*, 2021, **22**, 1122–1150.
- 20 S. K. Piasecki, J. Zheng, A. J. Axelrod, M. E. Detelich and A. T. Keatinge-Clay, *Proteins*, 2014, **82**, 2067–2077.
- 21 D. Kawasaki, A. Miyanaga, T. Chisuga, F. Kudo and T. Eguchi, *Biochemistry*, 2019, **58**, 4799–4803.
- 22 K. Watanabe, C. C. Wang, C. N. Boddy, D. E. Cane and C. Khosla, *J. Biol. Chem.*, 2003, **278**, 42020–42026.
- 23 J. Wu, T. J. Zaleski, C. Valenzano, C. Khosla and D. E. Cane, *J. Am. Chem. Soc.*, 2005, **127**, 17393–17404.
- 24 Y. Li, W. D. Fiers, S. M. Bernard, J. L. Smith, C. C. Aldrich and R. A. Fecik, *ACS Chem. Biol.*, 2014, **9**, 2914–2922.
- 25 R. Ueoka, J. Hashimoto, I. Kozono, T. Hashimoto, K. Kudo, N. Kagaya, H. Suenaga, H. Ikeda and K. Shin-ya, *Biosci. Biotechnol. Biochem.*, 2021, **85**, 890–894.
- 26 S. Omura, H. Ikeda, H. Matsubara and N. Sakakane, *J. Antibiot.*, 1980, **33**, 1570–1572.
- 27 C. C. Aldrich, B. J. Beck, R. A. Fecik and D. H. Sherman, *J. Am. Chem. Soc.*, 2005, **127**, 8441–8452.
- 28 D. A. Hansen, C. M. Rath, E. B. Eisman, A. R. Narayan, J. D. Kittendorf, J. D. Mortison, Y. J. Yoon and D. H. Sherman, *J. Am. Chem. Soc.*, 2013, **135**, 11232–11238.
- 29 I. H. Gilbert, M. Ginty, J. A. O'Neill, T. J. Simpson, J. Staunton and C. L. Willis, *Bioorg. Med. Chem. Lett.*, 1995, **5**, 1587–1590.
- 30 W. He, J. Wu, C. Khosla and D. E. Cane, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 391–394.
- 31 M. C. Tang, C. R. Fischer, J. V. Chari, D. Tan, S. Suresh, A. Chu, M. Miranda, J. Smith, Z. Zhang, N. K. Garg, R. P. St Onge and Y. Tang, *J. Am. Chem. Soc.*, 2019, **141**, 8198–8206.
- 32 G. J. Wormer, N. L. Villadsen, P. Norby and T. B. Poulsen, *Angew Chem. Int. Ed. Engl.*, 2021, **60**, 10521–10525.
- 33 In the initial attempts for the synthesis of 1a, we performed the thioesterification of enone-bearing carboxylic acid. However, the reaction was complicated, producing a trace amount of the desired 1a with inseparable impurities.
- 34 D. A. Evans, J. V. Nelson, E. Vogel and T. R. Taber, *J. Am. Chem. Soc.*, 1981, **103**, 3099–3111.
- 35 M. Dow, F. Marchetti, K. A. Abrahams, L. Vaz, G. S. Besra, S. Warriner and A. Nelson, *Chem.–Eur. J.*, 2017, **23**, 7207–7211.
- 36 D. B. Dess and J. C. Martin, *J. Org. Chem.*, 1983, **48**, 4155–4156.
- 37 D. B. Dess and J. C. Martin, *J. Am. Chem. Soc.*, 1991, **113**, 7277–7287.
- 38 K. Takai, K. Nitta and K. Utimoto, *J. Am. Chem. Soc.*, 1986, **108**, 7408–7410.
- 39 T. Okazoe, K. Takai and K. Utimoto, *J. Am. Chem. Soc.*, 1987, **109**, 951–953.
- 40 G. Q. Lin and W. C. Xu, *Tetrahedron*, 1996, **52**, 5907–5912.
- 41 The formation of the 6-membered lactones by the 1,2-addition to the enone moiety has been reported in the macrolide synthesis, as mentioned in ref. 42 and 43.
- 42 V. Velvadapu, T. Paul, B. Wagh, I. Glassford, C. DeBrosse and R. B. Andrade, *J. Org. Chem.*, 2011, **76**, 7516–7527.
- 43 H. S. Oh and H. Y. Kang, *J. Org. Chem.*, 2012, **77**, 1125–1130.
- 44 Y. K. Wu, J. H. Huang, X. Shen, Q. Hu, C. J. Tang and L. Li, *Org. Lett.*, 2002, **4**, 2141–2144.
- 45 N. C. Wilde, M. Isomura, A. Mendoza and P. S. Baran, *J. Am. Chem. Soc.*, 2014, **136**, 4909–4912.
- 46 R. Xuan, H. S. Oh, Y. Lee and H. Y. Kang, *J. Org. Chem.*, 2008, **73**, 1456–1461.
- 47 R. H. Lambalot and D. E. Cane, *J. Antibiot.*, 1992, **45**, 1981–1982.



- 48 A. Hagen, S. Poust, T. Rond, J. L. Fortman, L. Katz, C. J. Petzold and J. D. Keasling, *ACS Synth. Biol.*, 2016, **5**, 21–27.
- 49 Y. Li, G. J. Dodge, W. D. Fiers, R. A. Fecik, J. L. Smith and C. C. Aldrich, *J. Am. Chem. Soc.*, 2015, **137**, 7003–7006.
- 50 A. Zargar, R. Lal, L. Valencia, J. Wang, T. W. H. Backman, P. Cruz-Morales, A. Kothari, M. Werts, A. R. Wong, C. B. Bailey, A. Loubat, Y. Liu, Y. Chen, S. Chang, V. T. Benites, A. C. Hernandez, J. F. Barajas, M. G. Thompson, C. Barcelos, R. Anayah, H. G. Martin, A. Mukhopadhyay, C. J. Petzold, E. E. K. Baidoo, L. Katz and J. D. Keasling, *J. Am. Chem. Soc.*, 2020, **142**, 9896–9901.
- 51 A. T. Keatinge-Clay, *Nat. Prod. Rep.*, 2012, **29**, 1050–1073.
- 52 T. M. McCullough, A. Dhar, D. L. Akey, J. R. Konwerski, D. H. Sherman and J. L. Smith, *Structure*, 2023, **31**, 1109–1120.
- 53 L. S. Keiser, P. P. Gatenil, Y. Zhu, K. Deng, L. Waldburger, J. W. Gin, Y. Chen, E. E. K. Baidoo, C. J. Petzold, N. Lanclos, T. R. Northen, E. Englund and J. D. Keasling, *J. Am. Chem. Soc.*, 2025, **147**, 42237–42252.
- 54 S. V. Ley, M. N. Tackett, M. L. Maddess, J. C. Anderson, P. E. Brennan, M. W. Cappi, J. P. Heer, C. Helgen, M. Kori, C. Kouklovsky, S. P. Marsden, J. Norman, D. P. Osborn, M. Á. Palomero, J. B. J. Pavey, C. Pinel, L. A. Robinson, J. Schnaubelt, J. S. Scott, C. D. Spilling, H. Watanabe, K. E. Wesson and M. C. Willis, *Chem.–Eur. J.*, 2009, **15**, 2874–2914.
- 55 L. Venkatraman, C. C. Aldrich, D. H. Sherman and R. A. Fecik, *J. Org. Chem.*, 2005, **70**, 7267–7272.
- 56 T. Hashimoto, J. Hashimoto, I. Kozono, K. Amagai, T. Kawahara, S. Takahashi, H. Ikeda and K. Shin-ya, *Org. Lett.*, 2018, **20**, 7996–7999.
- 57 S. C. Tsai, H. Lu, D. E. Cane, C. Khosla and R. M. Stroud, *Biochemistry*, 2002, **41**, 12598–12606.
- 58 J. R. Whicher, S. Dutta, D. A. Hansen, W. A. Hale, J. A. Chemler, A. M. Dosey, A. R. Narayan, K. Hakansson, D. H. Sherman, J. L. Smith and G. Skiniotis, *Nature*, 2014, **510**, 560–564.
- 59 J. H. Kim, M. Komatsu, K. Shin-ya, S. Omura and H. Ikeda, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, 6828–6833.
- 60 A. J. Hughes and A. Keatinge-Clay, *Chem. Biol.*, 2011, **18**, 165–176.
- 61 J. M. Jez, J. L. Ferrer, M. E. Bowman, R. A. Dixon and J. P. Noel, *Biochemistry*, 2000, **39**, 890–902.

